Metropolis Healthcare has announced its unaudited consolidated financial results for the first quarter of financial year 2023.
Q1FY23 financial highlights
- Rs 261.7 crore non-COVID revenue*
- Rs 71.7 crore EBITDA (Before CSR & ESOP)
- Rs 33.6 crore profit after tax
Q1FY23 key highlights
- Non-COVID home visits revenue increased by 30 per cent YoY Rs 23 crore
- Specialised tests contributed 42 per cent to the non-COVID revenue
- EBITDA margin (Before CSR & ESOP) stood at 25.6 per cent
Ameera Shah, Promoter and Managing Director, Metropolis Healthcare said, “I am extremely pleased to share that we have recorded 26 per cent growth on year-on-year basis for non-COVID business inspite of the challenging business environment. COVID and COVID allied revenue witnessed a sharp fall as expected in line with the drop in number of COVID cases. Going ahead, we expect the non-COVID revenue to revert back to the sustainable growth rates recorded in pre-covid days. We at Metropolis will continue to build our scientific capabilities, expand our network of labs and patient collection centres, build a superior customer experience, and will also focus on wellness and chronic testing segment. We are excited about the differentiation we have been able to create over the years and believe our company has a long runway of growth.”
*Revenue excluding COVID PCR & COVID allied tests